Distinguished in Age-Related Macular Degeneration (ARMD)

Hendrik P. Scholl

Basel, BS, CH 
Distinguished in Age-Related Macular Degeneration (ARMD)
Basel, BS, CH 
OverviewLocationsClinical Research

Overview

Hendrik Scholl practices in Basel, Switzerland. Mr. Scholl is rated as a Distinguished expert by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Stargardt Macular Degeneration, Late-Onset Retinal Degeneration, Retinopathy Pigmentary Mental Retardation, Vitrectomy, and Corneal Transplant.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Age-Related Macular Degeneration (ARMD).

Gender
Male

Locations

Basel, BS, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE
Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Biological
Study Drug: rAAV2tYF-CB-hRS1
Study Phase: Phase 1/Phase 2
A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)
A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)
Enrollment Status: Completed
Publish Date: December 28, 2018
Intervention Type: Dietary supplement
Study Phase: Not Applicable
View 2 Less Clinical Trials

16 Total Publications

Variants in the AGBL5 gene are responsible for autosomal recessive Retinitis pigmentosa with hearing loss.
Variants in the AGBL5 gene are responsible for autosomal recessive Retinitis pigmentosa with hearing loss.
Journal: European journal of human genetics : EJHG
Published: May 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Scholl's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile